PMID- 36270340
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20221025
IS  - 1336-0329 (Electronic)
IS  - 1210-0668 (Linking)
VI  - 56
IP  - 4
DP  - 2022 Oct 1
TI  - The impact of type 2 diabetes duration on serum asymmetric dimethylarginine and 
      C-reactive protein concentration in Bosnian patients.
PG  - 271-278
LID - 10.2478/enr-2022-0029 [doi]
AB  - Objective. The present study assessed the impact of type 2 diabetes mellitus 
      (T2DM) duration on the serum asymmetric dimethylarginine (ADMA) and C-reactive 
      protein (CRP) concentration in Bosnian patients. Methods. Participants for this 
      cross-sectional study were randomly selected from the Family Medicine Clinic 
      (Sarajevo, Bosnia and Herzegovina). Serum ADMA concentration was determined by 
      ELISA. Serum high-sensitivity (hs-CRP) was determined by particle-enhanced 
      immunonephelometry. ANOVA test followed by Scheffe post-hoc test or 
      Kruskal-Wallis test followed by Man-Whitney test were used for statistical 
      analysis. Results. The study included 38 patients in up to 10 years diabetes 
      duration (</=10 years T2DM) group, 22 patients in greater than 10 years diabetes 
      duration (>10 years T2DM) group, and 60 controls. Serum ADMA concentration in the 
      >10 years T2DM group (1.81+/-0.15 mumol/L) was significantly higher compared to 
      serum ADMA concentration in the </=10 years T2DM group (1.38+/-0.41 mumol/L; p<0.001) 
      and in controls (0.62+/-0.15 mumol/L; p<0.001). A significant difference in serum 
      ADMA concentration was found between the <10 years T2DM group and the controls 
      (p<0.001). The serum CRP concentration in the >10 years T2DM group [5.95 
      (4.20-9.12) mg/L] was significantly higher compared to serum CRP concentration in 
      the <10 years T2DM group [2.35 (1.40-4.30) mg/L; p<0.001] and controls [0.85 
      (0.50-1.30) mg/L; p<0.001]. Significant difference in serum CRP concentration was 
      observed between the <10 years T2DM group and controls (p<0.001). Conclusions. 
      The present study showed an increase in the serum ADMA and CRP concentrations 
      with the advancement of T2DM. These results suggest that ADMA and CRP may serve 
      as indicators of endothelial dysfunction and chronic low-grade inflammation 
      progression in patients with T2DM. Larger prospective studies are required to 
      confirm the observed findings.
CI  - (c) 2022 Asija Zaciragic et al., published by Sciendo.
FAU - Zaciragic, Asija
AU  - Zaciragic A
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Dervisevic, Amela
AU  - Dervisevic A
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Avdagic, Nesina
AU  - Avdagic N
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Babic, Nermina
AU  - Babic N
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Valjevac, Amina
AU  - Valjevac A
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Lepara, Orhan
AU  - Lepara O
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
FAU - Huskic, Jasminko
AU  - Huskic J
AD  - Department of Human Physiology, Faculty of Medicine, University of Sarajevo, 
      Sarajevo, Bosnia and Herzegovina.
LA  - eng
PT  - Journal Article
DEP - 20221020
PL  - Germany
TA  - Endocr Regul
JT  - Endocrine regulations
JID - 9112018
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 63CV1GEK3Y (N,N-dimethylarginine)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Humans
MH  - *C-Reactive Protein/analysis
MH  - *Diabetes Mellitus, Type 2
MH  - Cross-Sectional Studies
MH  - Arginine
MH  - Inflammation
OTO - NOTNLM
OT  - C-reactive protein
OT  - asymmetric dimethylarginine
OT  - endothelial dysfunction
OT  - systemic low-grade inflammation
OT  - type 2 diabetes mellitus
EDAT- 2022/10/22 06:00
MHDA- 2022/10/26 06:00
CRDT- 2022/10/21 19:23
PHST- 2022/10/21 19:23 [entrez]
PHST- 2022/10/22 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
AID - enr-2022-0029 [pii]
AID - 10.2478/enr-2022-0029 [doi]
PST - epublish
SO  - Endocr Regul. 2022 Oct 20;56(4):271-278. doi: 10.2478/enr-2022-0029. Print 2022 
      Oct 1.